The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation

Highlights • Higher osteopontin plasma levels correlate with more hypoxic tumors at baseline.• Increased baseline osteopontin levels are associated with residual tumor hypoxia.• Absent early hypoxia response is linked with higher VEGF and CTGF levels in week 5.• Plasma hypoxic markers may serve as biomarkers favoring radiotherapy personalization.

• Publication year

  2022

• Venue

  Clinical and Translational Radiation Oncology

• Publication date

  2022-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ctro.2022.02.008PMID 35243023PMCID 8881198
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• De-Escalation Strategies of (Chemo)Radiation for Head-and-Neck Squamous Cell Cancers—HPV and Beyond

  2021cited by this paper
• Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation—results from a prospective pilot trial

  2021cited by this paper
• Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

  2021cited by this paper
• 18F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy

  2021cited by this paper
• Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.

  2021cited by this paper
• The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.

  2020cited by this paper
• Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity.

  2020cited by this paper
• Prognostic significance of serum osteopontin levels in small cell lung cancer

  2020cited by this paper
• Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial

  2020cited by this paper
• Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.

  2020cited by this paper
• [18F]-HX4 PET/CT hypoxia in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy: Prognostic results from two prospective trials

  2020cited by this paper
• Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial.

  2019cited by this paper
• Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer

  2019cited by this paper
• The Role of Osteopontin as a Diagnostic and Prognostic Biomarker in Sepsis and Septic Shock

  2019cited by this paper
• The role of osteopontin in the progression of solid organ tumour

  2018cited by this paper
• Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol

  2017cited by this paper
• Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.

  2017cited by this paper
• Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.

  2017cited by this paper
• Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients

  2017cited by this paper
• Galectin-3 induced by hypoxia promotes cell migration in thyroid cancer cells

  2017cited by this paper
• Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration

  2017cited by this paper
• Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer

  2016cited by this paper
• Trends in all-cause five-year mortality after head and neck cancers diagnosed over a period of 33 years. Focus on estimated degree of association with human papillomavirus

  2016cited by this paper
• Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.

  2016cited by this paper
• Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG

  2016cited by this paper
• Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials

  2016cited by this paper
• The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer.

  2016cited by this paper
• Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines

  2015cited by this paper
• Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas

  2014cited by this paper
• Serum levels of osteopontin as a prognostic factor in patients with oral squamous cell carcinoma

  2014cited by this paper
• The expression and clinical significance of connective tissue growth factor in advanced head and neck squamous cell cancer

  2014cited by this paper
• Incidence and survival trends of head and neck squamous cell carcinoma in the Netherlands between 1989 and 2011.

  2014cited by this paper
• Increased Circulation of Galectin-3 in Cancer Induces Secretion of Metastasis-Promoting Cytokines from Blood Vascular Endothelium

  2013cited by this paper
• Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection.

  2013cited by this paper
• Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer.

  2012cited by this paper
• FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.

  2012cited by this paper
• Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.

  2012cited by this paper
• Hypoxia-inducible factors in physiology and medicine.

  2012cited by this paper
• Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.

  2012cited by this paper
• Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis.

  2011cited by this paper
• Osteopontin as a marker of weight loss in lung cancer

  2011cited by this paper
• Prognostic Value of Radiobiological Hypoxia during Fractionated Irradiation for Local Tumor Control

  2011cited by this paper
• Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas.

  2009cited by this paper
• Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy.

  2009cited by this paper
• The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth.

  2009cited by this paper
• Plasma Osteopontin, Hypoxia, and Response to Radiotherapy in Nasopharyngeal Cancer

  2008cited by this paper
• Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure

  2008cited by this paper
• The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy.

  2008cited by this paper
• Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer.

  2007cited by this paper
• Hypoxia dose painting by numbers: a planning study.

  2007cited by this paper
• Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.

  2007cited by this paper
• Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas.

  2007cited by this paper
• Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system

  2006cited by this paper
• Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer

  2006cited by this paper
• Osteopontin and Mucosal Protection

  2006cited by this paper
• Influence of oxygen concentration and pH on expression of hypoxia induced genes.

  2005cited by this paper
• Galectin-1: a link between tumor hypoxia and tumor immune privilege.

  2005cited by this paper
• Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma.

  2005cited by this paper
• Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.

  2005influential reference
• Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum

  2005cited by this paper
• Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

  2004cited by this paper
• Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

  2004cited by this paper
• Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy.

  2004cited by this paper
• [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression

  2003cited by this paper
• Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas.

  2003cited by this paper
• An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.

  2003cited by this paper
• Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases.

  2002cited by this paper
• Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma

  2002cited by this paper
• Tumor Hypoxia and Systemic Levels of Vascular Endothelial Growth Factor (VEGF) in Head and Neck Cancers

  2001cited by this paper
• Treatment resistance of solid tumors

  2001cited by this paper
• Treatment resistance of solid tumors: role of hypoxia and anemia.

  2001cited by this paper
• Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells: potentiation by high glucose.

  2001cited by this paper
• Serum levels of vascular endothelial growth factor in patients with head and neck cancer

  2000cited by this paper
• Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma.

  2000cited by this paper
• Hypoxemia increases serum interleukin-6 in humans

  1997cited by this paper
• Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.

  1996cited by this paper
• The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.

  1953cited by this paper

• Is there a role for [18F]-FMISO PET to guide dose adaptive radiotherapy in head and neck cancer? A review of the literature

  2024cites this paper
• Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy

  2022cites this paper